Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/23999
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2022-01-11T09:07:18Z | - |
dc.date.available | 2022-01-11T09:07:18Z | - |
dc.date.issued | 2006-05 | - |
dc.identifier.citation | Ersoy, A. vd. (2006). ''Is glucocorticoid-induced osteonecrosis after kidney transplantation related to osteoporosis?''. Nephrology Dialysis Transplantation, 21(5), 1452-1453. | en_US |
dc.identifier.issn | 0931-0509 | - |
dc.identifier.uri | https://doi.org/10.1093/ndt/gfi342 | - |
dc.identifier.uri | https://academic.oup.com/ndt/article/21/5/1452/1822097 | - |
dc.identifier.uri | http://hdl.handle.net/11452/23999 | - |
dc.description.abstract | Osteopenia and osteonecrosis (ON) cause important longterm morbidity in renal transplant (Tx) recipients with increasing incidences because of longer graft survival and related drug exposure. A 38-year-old woman who started on haemodialysis in November 2001 had a renal Tx from a live relative in March 2003 due to chronic pyelonephritis with vesicoureteral reflux related end-stage renal disease. She had persistent secondary amenorrhoea 2 months before dialysis treatment. Throughout this period she had calcitriol and phosphorus binders for controlling secondary hyperparathyroidism. Her pre-Tx serum parathyroid hormone (PTH) was 73.2 pg/ml and body mass index (BMI) was 18.4 kg/m2 . Post-Tx immunosuppressive treatment was prednisolone (500 mg initially, then 30 mg/day), tapered to 25 mg/day by postoperative day 14, mycophenolate mofetil (2 g/day), cyclosporin (CsA; 100 mg/d) and daclizumab (a dose of 1 mg/kg, totalling five dosages with 2-week intervals). After an uneventful 4 weeks she complained of severe leg pain and symptoms of muscle weakness in the previous 4 days. The dose of prednisolone was tapered to 15 mg/day, but pain developed in both shoulders. Diffuse ON was diagnosed by hip and shoulder magnetic resonance imagings (MRI). At the time of diagnosis the total cumulative doses of prednisolone and CsA were 1220 mg and 2925 mg in 4 weeks, respectively. Serum creatinine was 0.7 mg/dl, calcium 10.5 mg/dl, Alkaline phosphatase (ALP) 271 IU/l, PTH 84 pg/ml, calcitonin 27 pg/ml and calcitriol 22.9 ng/dl. Bone mineral densities (BMD) of the lumbar spine and the hip region by Dual x-ray absorptiomtery (DEXA) after post-Tx 8 weeks were evaluated as osteoporosis with T scores of 3.2 and 3.9, respectively. Oral calcium, calcitriol and alendronate were added to the treatment. Her complaints regressed within 10 days. The dose of prednisolone was tapered to 10 mg/day at month 4 and to 5 mg/day at month 10. One year later, hip and shoulder MRIs showed normal findings. The respective post-Tx T scores of the lumbar spine and the femoral neck improved from -2.8 and -3.5 in the first year to -2.4 and -2.2 in the second year. Her serum creatinine level was 0.8 mg/dl with no complaint. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Oxford University Press | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Transplantation | en_US |
dc.subject | Urology & nephrology | en_US |
dc.subject | Kidney transplantation | en_US |
dc.subject | Kidney failure, chronic | en_US |
dc.subject | Humans | en_US |
dc.subject | Glucocorticoids | en_US |
dc.subject | Femur head necrosis | en_US |
dc.subject | Female | en_US |
dc.subject.mesh | Transplantation immunology | en_US |
dc.subject.mesh | Severity of illness index | en_US |
dc.subject.mesh | Risk assessment | en_US |
dc.subject.mesh | Prognosis | en_US |
dc.subject.mesh | Osteoporosis | en_US |
dc.subject.mesh | Magnetic resonance imaging | en_US |
dc.subject.mesh | Kidney transplantation | en_US |
dc.subject.mesh | Kidney failure, chronic | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Glucocorticoids | en_US |
dc.subject.mesh | Femur head necrosis | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Dose-response relationship, drug | en_US |
dc.subject.mesh | Densitometry, X-ray | en_US |
dc.subject.mesh | Adult | en_US |
dc.title | Is glucocorticoid-induced osteonecrosis after kidney transplantation related to osteoporosis? | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000237004900063 | tr_TR |
dc.identifier.scopus | 2-s2.0-33646178815 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-0710-0923 | tr_TR |
dc.contributor.orcid | 0000-0001-7482-668X | tr_TR |
dc.identifier.startpage | 1452 | tr_TR |
dc.identifier.endpage | 1453 | tr_TR |
dc.identifier.volume | 21 | tr_TR |
dc.identifier.issue | 5 | tr_TR |
dc.relation.journal | Nephrology Dialysis Transplantation | en_US |
dc.contributor.buuauthor | Ersoy, Alparslan | - |
dc.contributor.buuauthor | Kahvecioğlu, Serdar | - |
dc.contributor.buuauthor | Ersoy, Canan | - |
dc.contributor.buuauthor | Akdağ, İbrahim | - |
dc.contributor.buuauthor | Yurtsever, İsmail | - |
dc.contributor.buuauthor | Dilek, Kamil | - |
dc.contributor.researcherid | AAH-5054-2021 | tr_TR |
dc.contributor.researcherid | AAH-8861-2021 | tr_TR |
dc.identifier.pubmed | 16357048 | tr_TR |
dc.subject.wos | Transplantation | en_US |
dc.subject.wos | Urology & nephrology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | Pubmed | en_US |
dc.wos.quartile | Q1 (Urology & nephrology) | en_US |
dc.wos.quartile | Q2 (Transplantation) | en_US |
dc.contributor.scopusid | 35612977100 | tr_TR |
dc.contributor.scopusid | 55956719500 | tr_TR |
dc.contributor.scopusid | 6701485882 | tr_TR |
dc.contributor.scopusid | 8342488100 | tr_TR |
dc.contributor.scopusid | 8535041400 | tr_TR |
dc.contributor.scopusid | 56005080200 | tr_TR |
dc.subject.scopus | Kienboeck Disease; Femur Head Necrosis; Thighs | en_US |
dc.subject.emtree | Prednisolone | en_US |
dc.subject.emtree | Phosphate binding agent | en_US |
dc.subject.emtree | Parathyroid hormone | en_US |
dc.subject.emtree | Mycophenolic acid 2 morpholinoethyl ester | en_US |
dc.subject.emtree | Glucocorticoid | en_US |
dc.subject.emtree | Daclizumab | en_US |
dc.subject.emtree | Cyclosporin A | en_US |
dc.subject.emtree | Creatinine | en_US |
dc.subject.emtree | Calcium | en_US |
dc.subject.emtree | Calcitriol | en_US |
dc.subject.emtree | Calcitonin | en_US |
dc.subject.emtree | Alkaline phosphatase | en_US |
dc.subject.emtree | Alendronic acid | en_US |
dc.subject.emtree | Vesicoureteral reflux | en_US |
dc.subject.emtree | Shoulder pain | en_US |
dc.subject.emtree | Secondary hyperparathyroidism | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Parathyroid hormone blood level | en_US |
dc.subject.emtree | Osteoporosis | en_US |
dc.subject.emtree | Nuclear magnetic resonance imaging | en_US |
dc.subject.emtree | Muscle weakness | en_US |
dc.subject.emtree | Lumbar spine | en_US |
dc.subject.emtree | Letter | en_US |
dc.subject.emtree | Leg pain | en_US |
dc.subject.emtree | Kidney transplantation | en_US |
dc.subject.emtree | Kidney graft rejection | en_US |
dc.subject.emtree | Kidney failure | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Hip | en_US |
dc.subject.emtree | Hemodialysis | en_US |
dc.subject.emtree | Femur neck | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Dual energy X ray absorptiometry | en_US |
dc.subject.emtree | Drug dose regimen | en_US |
dc.subject.emtree | Disease severity | en_US |
dc.subject.emtree | Creatinine blood level | en_US |
dc.subject.emtree | Chronic pyelonephritis | en_US |
dc.subject.emtree | Case report | en_US |
dc.subject.emtree | Calcium blood level | en_US |
dc.subject.emtree | Calcitonin blood level | en_US |
dc.subject.emtree | Bone necrosis | en_US |
dc.subject.emtree | Bone density | en_US |
dc.subject.emtree | Body mass | en_US |
dc.subject.emtree | Amenorrhea | en_US |
dc.subject.emtree | Alkaline phosphatase blood level | en_US |
dc.subject.emtree | Adult | en_US |
Appears in Collections: | Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Ersoy_vd_2006.pdf | 180.07 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License